IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial.

"rna-seq data are available at the national center for biotechnology information's sequence read archive as bioproject number prjna1003129 ( https://dataview ncbi nlm nih gov/object/prjna1003129? reporting summary supplementary data 1 source data for tables1 and 2."

"Competing interests A.G., V.C., A.D., S.A., R.K., K.S., A.M., C.K., B.E., V.M., E.K., K.S., E.K., R.B., D.C., X.Z., V.S., C.H., N.M., A.S. and J.A.G. are Kymera Therapeutics employees and may have stock or stock options. J.D. and H.R. are former Kymera Therapeutics employees and may have stock or stock options. J.C. is a full-time consultant working for Kymera Therapeutics. All other authors (L.A., G.A., S.B., H.S., B.J.F., P.L. and A.A.) are employees of their respective companies; they were investigators from clinical sites in the trial and received payment for their participation in the trial."

"We thank the patients, their families and the study personnel involved in this trial. Kymera Therapeutics funded the study, data analysis and the writing and publication of this manuscript. This work was done under a collaboration agreement with Sanofi. M. DeFino of Acumen Medical Communications provided editorial support, which was paid for by Kymera Therapeutics. Data availability: The clinical data that support the findings of this study are not openly available owing to reasons of sensitivity and are available from the corresponding author (jared@kymeratx.com) upon reasonable request. RNA-seq data are available at the National Center for Biotechnology Informationʼs Sequence Read Archive as BioProject number PRJNA1003129 (https://dataview.ncbi.nlm.nih.gov/object/PRJNA1003129?reviewer=o2jfesi1s6rtlgcsoofigfnft5). Requests will be responded to within 3 weeks of receipt. Source data are provided with this paper."